trending Market Intelligence /marketintelligence/en/news-insights/trending/QZZDzLRLoaKZdjzYzfi7hA2 content esgSubNav
In This List

SpringWorks Therapeutics upsizes Nasdaq IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


SpringWorks Therapeutics upsizes Nasdaq IPO

SpringWorks Therapeutics Inc. upsized an IPO of its shares on Nasdaq and is now looking to sell 9 million shares.

The Connecticut-based biopharmaceutical company was previously looking to sell 7,352,941 shares. The IPO's price range still remains at between $16 per share and $18 per share.

Goldman Sachs & Co. LLC, Wedbush PacGrow, J.P. Morgan Securities LLC and Cowen and Co. LLC are the underwriters of the IPO and will have an option to buy up to an additional 1,350,000 shares.

SpringWorks Therapeutics plans to use the proceeds to further the clinical development of its drugs nirogacestat and mirdametinib, among other things.